| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| cabergoline | alpha-1a adrenergic receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.08 | approved | binder,antagonist |
| cabergoline | alpha-1b adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
NA | approved | binder |
| cabergoline | alpha-1d adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
NA | approved | binder |
| cabergoline | alpha-2a adrenergic receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.2 | approved | antagonist |
| cabergoline | alpha-2b adrenergic receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.3 | approved | antagonist |
| cabergoline | alpha-2c adrenergic receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.2 | approved | antagonist |
| cabergoline | beta-1 adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
NA | approved | binder |
| cabergoline | beta-2 adrenergic receptor | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
NA | approved | binder |
| cabergoline | d(1) dopamine receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.16 | approved | agonist |
| cabergoline | dopamine d1 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.16 | approved | agonist |
| cabergoline | dopamine d2 receptor | small molecule | Successful target | TTD , drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.36 | approved | agonist |
| cabergoline | dopamine d3 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.2 | approved | agonist |
| cabergoline | dopamine d4 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.2 | approved | agonist |
| cabergoline | dopamine d5 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.53 | approved | agonist |
| cabergoline | d(1) dopamine receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.53 | approved | agonist |
| cabergoline | 5-hydroxytryptamine receptor 1a | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.16 | approved | agonist |
| cabergoline | 5-hydroxytryptamine receptor 1b | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.2 | approved | agonist |
| cabergoline | 5-hydroxytryptamine receptor 1d | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.21 | approved | agonist |
| cabergoline | 5-hydroxytryptamine receptor 2a | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.15 | approved | agonist |
| cabergoline | 5-hydroxytryptamine receptor 2b | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.37 | approved | agonist |
| cabergoline | 5-hydroxytryptamine receptor 2c | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
0.22 | approved | agonist |
| cabergoline | 5-hydroxytryptamine receptor 7 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Parkinsonian Disorders[MeSHID:D020734] Prolactinoma[MeSHID:D015175] Syndrome[MeSHID:D013577] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hyperprolactinemia[MeSHID:D006966] |
NA | approved | antagonist |
| click here to return to the previous page | ||||||||